This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New […]
Source
Pharmaceutical companies with the most ‘New Patient Population’ drugs Read Post »
Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one […]
Source
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Annual Drug Patent Expirations for NASCOBAL Nascobal is a drug marketed by Par Pharm and Endo Pharms Inc and is […]
Source
New patent expiration for Endo Pharms drug NASCOBAL Read Post »
Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. […]
Source
Annual Drug Patent Expirations for BAXDELA Baxdela is a drug marketed by Melinta and is included in two NDAs. It […]
Source
This chart shows the drugs with the most patents in Singapore. Patents must be filed in each country (or, in […]
Source
Which pharmaceutical drugs have the most drug patents in Singapore? Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Expiring drug patents are continuously driving innovation, as branded firms seek out new high-margin opportunities. Examining the patent expirations by […]
Source
Drugs facing the most patent expirations this year Read Post »